Masitinib mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Masitinib mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
56
Registered trials
32
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Masitinib mesylate can convert its Small molecule drug profile and LYN x PDGFRα x PDGFRβ x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Masitinib mesylate (query alias: masitinib) |
|---|---|
| Modality / target | Small molecule drug; LYN x PDGFRα x PDGFRβ x c-Kit; LYN inhibitors, PDGFRα inhibitors, PDGFRβ inhibitors |
| Highest global status | Phase 3 |
| Originator | AB Science SA |
| Active developers | AB Science SA |
The MCP disease footprint includes Amyotrophic Lateral Sclerosis, Melanoma, Metastatic Colorectal Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05441488 | Phase 3 | Suspended | 800 | Time to confirmed progression |
| NCT05564169 | Phase 3 | Not yet recruiting | 600 | Absolute change from baseline in iADRS score at week 24 |
| NCT07174492 | Phase 3 | Not yet recruiting | 412 | ALSFRS-R |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Evaluating the efficacy of tyrosine kinase inhibitors and other targeted therapies in imatinib-resistant gastrointestinal stromal tumors: A comprehensive Bayesian network meta-analysis.
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: PFS = 9.33 month ( 4.15 - 14.88); PFS = 8.68 month ( 3.47 - 14.13); PFS = 11.78 month ( 0.29 - 23.49)
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: -; EDSS score(3-month) = -37 %
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
Phase 2; n=95; evaluation: Positive. Reported fields: Efficacy = odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. ; Efficacy = odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Masitinib mesylate addresses Amyotrophic Lateral Sclerosis, Melanoma, Metastatic Colorectal Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: LYN x PDGFRα x PDGFRβ x c-Kit records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-11-27 | Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes | Phase 2 | Financial terms not disclosed |
| 2022-07-21 | NeuroFront secures option for development and commercialization of Novaremed's NRD.E1 for PDPN in Greater China and Singapore. | Phase 2 | US$130.0M stated total |
| 2021-08-24 | Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate MLR-1023 | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Synthesis method of masitinib”. The milestone feed surfaced a patent-application signal described as “Masitinib for the treatment of castrate-resistant prostate cancer”. The milestone feed surfaced a patent-application signal described as “Application of masitinib in preparation of medicine for resisting tick-borne encephalitis virus, west nile virus, yellow fever virus and chikungunya virus infection”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
